Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endogenous GLP-1 and Islet Function in T2DM
NCT04466618Phase 3Completed
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of exendin 9-39 in type 2 diabetes mellitus (T2DM). Started Apr 2021; status: completed.
02
Drugs
exendin 9-39
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04466618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466618.